← FDA DRUG APPROVALS

FDA ANDA · ANDA213256

LEVOTHYROXINE SODIUM

Sponsor: ANI PHARMS

APPLICATION
ANDA213256
TYPE
ANDA
ORIGINAL APPROVAL
2021-01-06
LATEST ACTION
2021-01-06
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

LEVOTHYROXINE SODIUMDiscontinued
LEVOTHYROXINE SODIUM 0.125MG · CAPSULE · ORAL
LEVOTHYROXINE SODIUMDiscontinued
LEVOTHYROXINE SODIUM 0.088MG · CAPSULE · ORAL
LEVOTHYROXINE SODIUMDiscontinued
LEVOTHYROXINE SODIUM 0.1MG · CAPSULE · ORAL

Approval history

2021-01-06UNKNOWN · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →